Veru (VERU) to Release Quarterly Earnings on Monday

Veru (NASDAQ:VERU) is expected to be posting its Q4 2025 results before the market opens on Monday, December 15th. Analysts expect Veru to post earnings of ($0.49) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, December 16, 2025 at 12:00 AM ET.

Veru Stock Performance

Shares of Veru stock opened at $2.49 on Monday. Veru has a one year low of $2.11 and a one year high of $14.20. The stock’s fifty day moving average is $3.20 and its 200 day moving average is $4.26. The stock has a market cap of $36.50 million, a P/E ratio of -1.13 and a beta of -1.00.

Hedge Funds Weigh In On Veru

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in shares of Veru during the second quarter worth about $220,000. Osaic Holdings Inc. boosted its stake in Veru by 11.9% in the 2nd quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock worth $152,000 after purchasing an additional 27,954 shares during the period. Qube Research & Technologies Ltd bought a new position in Veru in the 2nd quarter worth approximately $152,000. Sender Co & Partners Inc. grew its holdings in Veru by 82.8% during the 2nd quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock valued at $139,000 after buying an additional 107,911 shares in the last quarter. Finally, Raymond James Financial Inc. raised its position in shares of Veru by 48.3% during the second quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after buying an additional 67,178 shares during the last quarter. Institutional investors own 47.16% of the company’s stock.

Analyst Upgrades and Downgrades

VERU has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research report on Wednesday, October 8th. Raymond James Financial cut their price objective on Veru from $30.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, August 13th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $25.00.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.